We have used the proteasome inhibitor bortezomib to sensitize human tumor cell lines to apoptosis mediated by death ligands, in particular the protein TRAIL. Also we have performed studies with antibodies that act as agonists to the TRAIL death receptors. The agonist antibodies may offer specific advantages for cancer therapy. There are 4 well-defined TRAIL receptors in humans, yet only 2 of them death receptor 4 (DR4) and death receptor 5 (DR5) send the apoptotic death signal. Therefore specific agonist antibodies to these receptors may be more selective than the TRAIL protein itself that can bind to all of the receptors. In addition antibodies tend to have a much longer half-life that the TRAIL protein in vivo, so their effects may be more potent and longer lasting. Bortezomib, a novel anticancer agent that inhibits the proteasome complex of enzymes recently was approved by the FDA for the therapy of multiple myeloma as a single agent. We have shown that in a panel of 50 human tumor cell lines, bortezomib sensitized about 45% of these cells to the apoptotic effects of TRAIL, about 25% to the apoptotic effects of Fas Ligand and less than 7 % to apoptosis by TNF. Since this proteasome inhibitor was very efficient in sensitizing tumor cells to TRAIL we studied this sensitization in more detail. In mouse models of renal cancer and breast cancer we showed that agonist antibodies to the mouse TRAIL death receptor DR5 had significantly enhanced pro-apoptotic activity in vitro in the presence of the proteasome inhibitor bortezomib. More importantly, this combination of agents had an improved therapeutic effect over either agent alone in experimental lung metastases models of both the renal and breast carcinomas in vivo. In addition the therapeutic combination did not cause any obvious toxicity in the mice on examination of a large number of organs. This was the first demonstration, to our knowledge, that this combination could have therapeutic anticancer efficacy in vivo in the absence of significant toxicity. There are currently clinical trails in progress using bortezomib and agonist antibodies to the TRAIL death receptor 4 in patients with multiple myeloma. We investigated the molecular basis of this sensitization in more detail. Cell death by apoptosis in response to the death ligands can proceed by 2 pathways. These are the extrinsic pathway, where the signaling from the death ligand death receptors is strong and directly signals cell death by setting off a cascade of enzymes. Alternatively for the intrinsic pathway, signaling from the death receptors is weaker and subsequent damage to the mitochondria of the cell is necessary for the cell death to occur. Using human renal carcinoma cells that are either sensitized or resistant to the effects of bortezomib on TRAIL-driven apoptosis, we concluded that the major effects of bortzomib were on amplifying the extrinsic apoptotic pathway. However exactly how a proteasome inhibitor amplifies this signaling at the molecular level is unclear and is under further investigation. In collaboration with the Molecular Targeting Development Program (MTDP) of the NCI we have also established a high-throughput screen to identify novel agents that can sensitize human cancer cells to TRAIL-mediated apoptosis. Over 18,000 pure synthetic compounds or natural products were screened and 18 compounds were identified for further study, 14 pure products and 4 synthetic compounds. Six of the compounds have been studied in more detail. None are proteasome inhibitors, but most may be DNA-damaging agents. Studies on these compounds, and the high-throughput testing of purified compounds from a wide variety of various extracts that the MTDP possesses are currently underway.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011056-02
Application #
7966001
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2009
Total Cost
$510,470
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Xu, Ya-Ming; Wijeratne, E M Kithsiri; Brooks, Alan D et al. (2018) Cytotoxic and other withanolides from aeroponically grown Physalis philadelphica. Phytochemistry 152:174-181
Xu, Ya-Ming; Brooks, Alan D; Wijeratne, E M Kithsiri et al. (2017) 17?-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-? Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships. J Med Chem 60:3039-3051
Xu, Ya-Ming; Wijeratne, E M Kithsiri; Babyak, Ashley L et al. (2017) Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells. J Nat Prod 80:1981-1991
Tewary, Poonam; Gunatilaka, A A Leslie; Sayers, Thomas J (2016) Using natural products to promote caspase-8-dependent cancer cell death. Cancer Immunol Immunother :
Pellom Jr, Samuel Troy; Dudimah, Duafalia Fred; Thounaojam, Menaka Chanu et al. (2015) Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 7:1011-22
Shanker, Anil; Pellom Jr, Samuel T; Dudimah, Duafalia F et al. (2015) Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res 75:5260-72
Canter, Robert J; Ames, Erik; Mac, Stephanie et al. (2014) Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer 14:756
Weiss, Jonathan M; Subleski, Jeff J; Back, Tim et al. (2014) Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/?CD40 therapy. J Immunol 192:5821-9
Whitson, Emily L; Sun, Han; Thomas, Cheryl L et al. (2012) Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima. J Nat Prod 75:394-9
Henrich, Curtis J; Thomas, Cheryl L; Brooks, Alan D et al. (2012) Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis. Apoptosis 17:79-89

Showing the most recent 10 out of 16 publications